Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies
- PMID: 8364927
Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies
Abstract
We have previously described anti-epidermal growth factor (EGF) receptor monoclonal antibodies (MAbs) which can block binding of transforming growth factor alpha (TGF-alpha) and EGF to receptors and inhibit activation of receptor tyrosine kinase. Studies with these MAbs involving cell cultures and nude mouse xenografts demonstrated their capacity to inhibit the growth of a variety of tumor cell lines, which express EGF receptors and TGF-alpha and appear to depend upon receptor activation for cell proliferation. To explore the mechanism(s) by which anti-EGF receptor 225 MAb inhibits cell proliferation, we have compared the activity of native 225 MAb with the response to bivalent 225 F(ab')2 and monovalent 225 Fab' fragments. Both native 225 MAb and its fragments could inhibit the binding of 125I-EGF to EGF receptors. Scatchard analysis revealed that the Kd of 225 F(ab')2 is comparable to that of 225 MAb (1 nM), whereas the Kd of 225 Fab' is 5 nM. Both bivalent 225 MAb and 225 F(ab')2 and monovalent 225 Fab' were able to completely inhibit TGF-alpha-induced EGF receptor tyrosine kinase activation, as assayed by autophosphorylation of tyrosine residues of EGF receptors on MCF10A nonmalignant human mammary cells, MDA468 human breast adenocarcinoma cells, and A431 human vulvar squamous carcinoma cells. The bivalent forms of MAb could inhibit proliferation stimulated by endogenous (autocrine) TGF-alpha in cultures of these three cell lines. They also blocked growth stimulation by added exogenous TGF-alpha in cultures of MCF10A cells and the growth-inhibitory effect of exogenous TGF-alpha upon MDA468 and A431 cell cultures. Monovalent 225 Fab' had weaker inhibitory effects upon the proliferation of these cell lines. To determine whether the in vivo antiproliferative activity of anti-EGF receptor MAb can occur without the participation of the Fc portion of MAb, the capacities of 225 F(ab')2 and native 225 MAb to inhibit growth of s.c. A431 cell xenografts were compared. Equimolar amounts of either 225 MAb or 225 F(ab')2 were administered at intervals equivalent to the half-lives of the molecules, to attempt to maintain comparable plasma levels. Both 225 MAb and 225 F(ab')2 inhibited A431 cell xenograft growth in a dose-dependent manner, with a more sustained response in the case of the intact antibody.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies.J Natl Cancer Inst Monogr. 1992;(13):125-31. J Natl Cancer Inst Monogr. 1992. PMID: 1389685 Review.
-
Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells.J Biol Chem. 1994 Nov 4;269(44):27595-602. J Biol Chem. 1994. PMID: 7961676
-
Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.Cancer Res. 1986 Nov;46(11):5592-8. Cancer Res. 1986. PMID: 3756906
-
Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.J Immunol. 1986 Jun 1;136(11):3945-52. J Immunol. 1986. PMID: 3084650
-
The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies.Semin Cancer Biol. 1990 Oct;1(5):339-44. Semin Cancer Biol. 1990. PMID: 2103507 Review.
Cited by
-
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1815-20. doi: 10.1073/pnas.1220763110. Epub 2013 Jan 14. Proc Natl Acad Sci U S A. 2013. PMID: 23319610 Free PMC article.
-
Copper-64 Radiopharmaceuticals for Oncologic Imaging.PET Clin. 2009 Jan;4(1):49-67. doi: 10.1016/j.cpet.2009.04.013. PET Clin. 2009. PMID: 27156895 Free PMC article.
-
Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.Br J Cancer. 2015 Sep 29;113(7):1010-9. doi: 10.1038/bjc.2015.319. Epub 2015 Sep 15. Br J Cancer. 2015. PMID: 26372697 Free PMC article.
-
Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.Mol Cancer Ther. 2012 Nov;11(11):2429-39. doi: 10.1158/1535-7163.MCT-12-0101-T. Epub 2012 Aug 27. Mol Cancer Ther. 2012. PMID: 22927667 Free PMC article.
-
Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research.Cancer Biother Radiopharm. 2009 Aug;24(4):379-93. doi: 10.1089/cbr.2009.0674. Cancer Biother Radiopharm. 2009. PMID: 19694573 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials